crypto coins and their value Block

Guoyuan Securities: A special dividend plan was drawn up and announced by Guoyuan Securities. On December 13, 2024, the company held the 20th meeting of the 10th Board of Directors and the 11th meeting of the 10th Board of Supervisors, at which the Proposal on Special Dividend Plan was reviewed and approved. As of September 30, 2024, the accumulated undistributed profit of the company was 7.743 billion yuan, and the accumulated distributable profit of the parent company was 5.262 billion yuan. In order to enhance the investor's sense of gain and improve the investor's return level, the company has drawn up a special dividend plan: based on the existing total share capital of 4.364 billion shares, a cash dividend of 0.60 yuan will be distributed to all shareholders for every 10 shares, and a total cash dividend of 262 million yuan will be distributed. No bonus shares will be distributed, and capital will not be increased from the provident fund.BMO raised the target price of Chevron from $170 to $175.Kangxinuo Bio: Dong Xiaoman was appointed as the new general partner of Shanghai Qianxizhi, and Kangxinuo Bio (06185) issued an announcement. On December 13, 2024, Dr. Zhu informed the board of directors that in view of the need for sufficient time to manage the employee stock ownership platform, all the partners of the employee stock ownership platform unanimously decided to appoint Well Lee as the new general partner of Shanghai Qianxiyi and Shanghai Qianxirui respectively, and Dong Xiaoman as the new general partner of Shanghai Qianxizhi. Therefore, Dr. Zhu is no longer the general partner of the employee stock ownership platform and no longer has the right to exercise the voting rights of the shares held by the employee stock ownership platform.

Kang Enbei: Amikacin Sulfate Injection is planned to win the bid for the tenth batch of national centralized drug purchase. On December 12th, Kang Enbei and its wholly-owned subsidiary Jinhua Kang Enbei participated in the bidding for the tenth batch of national centralized drug purchase organized by the National Joint Procurement Office for Centralized Drug Purchase and Use. After the bid opening and bid evaluation by the Joint Procurement Office, the company's product Amikacin Sulfate Injection plans to win the bid for this centralized procurement, and the supply provinces have been selected according to the market potential of each province. The successful results will be officially released after being publicized by the Joint Procurement Office. Amikacin sulfate injection is suitable for the treatment of serious infections caused by Pseudomonas aeruginosa, other Pseudomonas, Escherichia coli and other sensitive gram-negative bacilli and Staphylococcus (methicillin-sensitive strains). Compared with the original price, the price of the product to be selected this time has dropped to a certain extent.Market News: US Secretary of State Blinken met with Iraqi Prime Minister in Baghdad to discuss the Syrian issue.Market News: Director of South Korea's National Police Agency will be arrested.

Market news: Sam Altman, founder of OpenAI, will donate $1 million to the inauguration fund of President-elect Trump. According to reports, Altman plans to donate to the Presidential Inaugural Committee in his own name, instead of directly donating by OpenAI.The US import price index in November was 1.3% year-on-year, expected to be 1%, and the previous value was 0.8%. The annual export price index of the United States in November was 0.8%, expected to be 0.3%, and the previous value was-0.10%.Xinxiangwei: Shareholder Xinyu Yijiade intends to reduce its shareholding by no more than 1%. Xinxiangwei announced that as of the disclosure date, Shareholder Xinyu Yijiade holds 20,175,800 shares of the company, accounting for 4.39% of the company's total share capital. Xinyu Yijiade plans to reduce the number of shares of the company by no more than 4,595,300 shares through centralized bidding or block trading of Shanghai Stock Exchange within 90 days after 15 trading days from the date of announcement, and the proportion of reduced shares in the company's total share capital is no more than 1%.